New mAbs on the Block: A (Rocking) Research Update on Biosimilar Uptake and Benefit Design Strategies

Published: March 16, 2022

2022 pbconference feature

– Describe the therapeutic areas, pipeline, and regulatory environment affecting the biosimilar landscape
– Report results of current research on barriers to biosimilar adoption and impact of benefit design and formulary policies on utilization
– Discuss prospective payer management strategies in anticipation of market entry of pharmacy benefit biosimilars

Author(s)/Presenter(s):

Cate Lockhart, MS, PharmD, Ph.D., Executive Director, Biologics and Biosimilars Collective Intelligence Consortium

Jennifer Snow, MPH, Vice President of Reimbursement Policy Insights, AmerisourceBergen/ Xcenda

View All Resources